- Home
- MTNB vs CANF Comparison
MTNB vs CANF Comparison
Compare MTNB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- CANF
- Stock Information
- Founded
- MTNB 2013
- CANF 1994
- Country
- MTNB United States
- CANF Israel
- Employees
- MTNB N/A
- CANF N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- CANF Health Care
- Exchange
- MTNB Nasdaq
- CANF Nasdaq
- Market Cap
- MTNB 9.7M
- CANF 9.6M
- IPO Year
- MTNB N/A
- CANF N/A
- Fundamental
- Price
- MTNB $1.73
- CANF $0.65
- Analyst Decision
- MTNB Hold
- CANF Strong Buy
- Analyst Count
- MTNB 1
- CANF 2
- Target Price
- MTNB N/A
- CANF $14.50
- AVG Volume (30 Days)
- MTNB 118.5K
- CANF 165.4K
- Earning Date
- MTNB 11-12-2025
- CANF 08-26-2025
- Dividend Yield
- MTNB N/A
- CANF N/A
- EPS Growth
- MTNB N/A
- CANF N/A
- EPS
- MTNB N/A
- CANF N/A
- Revenue
- MTNB N/A
- CANF $560,000.00
- Revenue This Year
- MTNB N/A
- CANF $461.72
- Revenue Next Year
- MTNB N/A
- CANF N/A
- P/E Ratio
- MTNB N/A
- CANF N/A
- Revenue Growth
- MTNB N/A
- CANF N/A
- 52 Week Low
- MTNB $0.47
- CANF $0.63
- 52 Week High
- MTNB $4.25
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- MTNB 52.72
- CANF 36.39
- Support Level
- MTNB $1.59
- CANF $0.64
- Resistance Level
- MTNB $1.88
- CANF $0.68
- Average True Range (ATR)
- MTNB 0.13
- CANF 0.02
- MACD
- MTNB -0.04
- CANF 0.01
- Stochastic Oscillator
- MTNB 28.00
- CANF 49.75
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).